Pine.Bio is changing the clinical bioinformatics speace by applying it's unique biAssociation engine to identify meaningful links between omics and clinical data, empowering better decisions and providing more options to patients.

1. PINEBIOAnalytics for molecular data in healthcare

3. CLINICAL DATA
GENOMICS
TRANSCRIPTOMICS
MICROBIOME
PROTEOMICS
EPIGENETICS
disease symptoms

4. CANCER
will this affect my family?
how long do I have?
what exactly is going on?
what is the best treatment?

5. 1,600,000
People die from cancer every
year in the US alone…

6. 24%
relapse or exhaust
standard of care

7. radiologist
medical
oncologist
surgical
oncologist
patient
pathologist

8. drug interactions
clinical trials
co-morbidities
epigenetic biomarkers
circulating tumor cells
copy number variation
new screens
combination therapies
resistance development
cfDNA markers
micro biome variation

9. PERSONALIZED CARE
PRECISION INSIGHT
data aggregation
better decisions
PINEBIO
research and discoverymolecular diagnostics

10. ANALYTICAL DASHBOARDS
PERSONALIZED CLINICAL INTERFACE

11. POWERFUL DATA ANALYSIS ENVIRONMENT
PROTEIN-DRUG
INTERACTIONS
STRUCTURAL
SCREENING
MUTATION
ANALYSIS

12. 1
2
3
ACADEMIC HOSPITALS PHARMA COMPANIES
BUSINESS MODEL
SAAS LICENSE SERVICES DATA+ +
RESEARCH TEAMS

13. less
headaches
for doctors
more
options for
patients

14. DR. ALFRED TAUBER DR. LEONID BRODSKY
Established one of the first bioinformatics labs at Lomonosov Moscow State
University in 1989. Dr. Leonid Brodsky has been leading bioinformatics research,
computational biology and systems biology modeling for over 30 years. His
expertise and methods contributed to numerous scientific discoveries and
publications. Currently, he is a Senior Reseach associate, and the Director of the
Tauber Bioinformatics Research Center in University of Haifa
Zoltan Kohn Professor Emeritus of Medicine at Boston University. Originally trained
as a biochemist and hematologist. Aside from over 125 research publications in
biochemistry and cell biology, Tauber has published extensively on 19th and 20th
century biomedicine, the development of modern immunology, the doctor-patient
relationship, and contemporary science studies. In 2013 Tauber was appointed
Chairman of the Board of Governors of the University of Haifa.
COMPANY FOUNDERS

15. CORE TEAM
ELIA BRODSKY AVI TITIEVSKY PRIYAL DE ZOYSAJACLYN WILLIAMS
Harvard Business School
HBX CORe, Bar Ilan Applied
Mathematics, BA in Visual
Communications and
Marketing. A number of
previous startups as founder
or co-founder.
MS in Computer Science and
Ph.D. candidate in Machine
Learning for Systems
Engineering. Has been
working closely with TBRC
for the past 6 years at Haifa
University.
MS in Microbiology from
University of South
Mississippi. Experience in lab
management, genomics and
bioinformatics and several
publications in microbiology.
Background in big Pharma
and tech companies such as
Seven Bridges, Life
technologies. Ph.D. in
BioScience and
Biotechnology.

16. TRACTION & MILESTONES:
in October 2016, our multi-
omics platform was awarded
the grand prize of $20,000 in a
startup competition organized
by the Pistoia Alliance, a
professional organization that
brings together big Pharma
and tech companies
Starting in March 2017, our team
is collaborating on a DARPA-
funded projects with researchers
from University of San Francisco,
Boston University, CDC, IBM and
others. This a multi-million dollar
project seeks to develop a new
therapeutic for infectious
diseases.
For the past several months, our team has
participated in a number of business
accelerator programs, including the
Propeller Health Accelerator and the
CAPITALx program run by the Idea
Village. These programs and the team at
the New Orleans BioInnovation Center are
helping prepare our company for growth.

17. VALIDATION PROJECTS AND EARLY ADOPTERS:
LOW FREQUENCY
MUTATION DETECTION IN
VIROLOGY: COLLABORATION
WITH UCSF, STANFORD AND
OTHERS TO DEVELOP A
METHOD OF HOST-
PATHOGEN INTERACTIONS
USING ULTRA DEEP
SEQUENCING.
DARPA INTERCEPT PROGRAM:
WORKING WITH RESEARCH AND
MODELING TEAMS FROM UCSF,
BU, STANFORD AND IBM AS A
DATA ANALYTICS AND
MANAGEMENT PLATFORM
PROVIDER. THE OBJECTIVE OF
THE PROJECT IS DEVELOPMENT
OF NEW THERAPEUTICS
CLINICAL TRIALS DATA:
WORKING ON A
CLINICAL TRIAL DATASET
FOR ACCORD
THERAPEUTICS TO
IDENTIFY BIOMARKERS
FOR DRUG RESPONSE
CLINICAL CANCER STUDIES:
A NUMBER OF VALIDATION
PROJECTS WITH RESEARCHERS AT
LSU HEALTH SCIENCES AND TULANE
MEDICAL SCHOOL TO DEVELOP
EFFECTIVE WORKFLOWS AROUND
EARLY DETECTION OF PATIENTS
WHERE MOLECULAR INSIGHT CAN
LEAD TO MORE EFFECTIVE
TREATMENTS
BASIC RESEARCH PROJECTS:
COLLABORATION WITH A
NUMBER OF RESEARCHERS
ON TARGET DISCOVERY AND
ANALYSIS OF MULTI-OMICS
DATASETS FOR PLATFORM
DEVELOPMENT AND
REFINEMENT
OCT. 2015 DEC. 2015 JULY. 2016 MARCH. 2017 APRIL. 2017

18. elia@pine.bio